[ad_1]
Sinofarm in China works differently from Western manufacturers that have been licensed so far, because its vaccine contains an inactivated virus, which is not suitable for reproduction in the human body. These trigger the body’s own immune response to develop protection.
The effectiveness of the vaccine is reported to be in the range of 80 to 90 percent. According to media reports, the company has also developed two vaccines, both in the third phase of clinical trials. This is largely done overseas, but it has already been administered to many in China as part of an emergency program launched in the summer.
The vaccines being tested can be given to people who are at higher risk of infection because of their work, such as health workers or border guards. The program will be expanded in the winter and port workers will also be able to receive the vaccine, who will be in contact with packages from abroad.
Although the Chinese company has not yet provided details of the third phase of clinical trials, data are already available from the countries where the vaccine was tested.
The United Arab Emirates said they were conducting tests on them.
An efficacy of 86 percent was observed, as well as the need for two doses to achieve protection.
In Egypt, about 3,000 people received the vaccine, with no serious side effects, just milder effects like fever, redness at the injection site or cough.
By November, around a million people had been vaccinated in China and serious side effects had not been experienced here either. Sixty thousand Chinese have already visited the severely infected areas, where they have been vaccinated with one of the five vaccines developed by China, and none of them have been diagnosed with a coronavirus infection since then, a Chinese media correspondent said.
The advantage of the Chinese vaccine is that it requires a temperature of between 2 and 6 degrees Celsius for its application, which is minus 70 degrees Celsius for Pfizer’s vaccine in the US Sinopharm began testing the domestic delivery processes last week to prepare for uninterrupted supply once marketing authorization is granted.
[ad_2]
